产品说明(Description)
Recombinant Human Interleukin-2 is produced by our E.coli expression system and the target gene encoding Ala21-Thr153 is expressed.
Accession #: P60568
Known as: Interleukin-2; IL-2; T-Cell Growth Factor; TCGF; Aldesleukin; IL2
制剂(Formulation)
Lyophilized from a 0.2 μm filtered solution of 10mM sodium citrate, pH 4.0.
质量控制(Quality Control)
Purity: Greater than 95% as determined by reducing SDS-PAGE.
Endotoxin: Less than 0.0./01 ng/μg (0.01 EU/μg) as determined by LAL test.
Bioactivity: | Bioactivity-BLI: | |
|
| |
Measured in a cell proliferation assay using CTLL-2 mouse cytotoxic T cells. The specific activity of Recombinant Human IL-2 is ≥1×107 IU/mg. | Loaded Human IL-2RB-Fc(Cat#CJ82) on Protein A Biosensor, can bind Human IL-2(Cat#C013) with an affinity constant of 0.29 uM as determined in BLI assay. | |
Bioactivity-BLI: | ||
|
| |
Loaded Human IL-2RA-Fc(Cat#CJ78) on Protein A Biosensor, can bind Human IL-2(Cat#C013) with an affinity constant of 17.0 nM as determined in BLI assay. | Loaded Human IL-2RB-His(Cat#CJ81) on HIS1K Biosensor, can bind Human IL-2(Cat#C013) with an affinity constant of 0.27 uM as determined in BLI assay. | |
|
| |
Loaded Mouse IL-2RA-His(Cat#CK67) on HIS1K Biosensor, can bind Human IL-2(Cat#C013) with an affinity constant of 21 nM as determined in BLI assay. | Loaded Biotinylated Human IL-2RB-His-Avi(Cat#CY31) on HIS1K Biosensor, can bind Human IL-2(Cat#C013) with an affinity constant of 0.27 uM as determined in BLI assay. |
复溶(Reconstitution)
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
保存(Storage)
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months.
背景(Background)
Interleukin-2(IL-2) is an interleukin, a type of cytokine signaling molecule in the immune system，belongs to the IL-2 family. It is a powerful immunoregulatory lymphokine produced by T-cells in response to antigenic or mitogenic stimulation. IL-2/IL-2R signaling is required for T-cell proliferation and other fundamental functions that are essential for the immune response. IL-2 stimulates growth and differentiation of B-cells, NK cells, lymphokine-activated killer cells, monocytes, macrophages and oligodendrocytes.
电泳(SDS-PAGE)
A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb[J]. Yang Wu. et al. Cancer Gene Therapy. 2021.
MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity[J]. Xiaochen Zhai. et al. American Journal of Cancer Research. 2021.
Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma[J]. Peng-Fei Zhang. et al. Molecular Cancer. 2020.
MicroRNA124-IL6R Mediates the Effect of Nicotine in Inflammatory Bowel Disease by Shifting Th1/Th2 Balance Toward Th1[J]. Zhen Qin. et al. Frontiers in Immunology. 2021.
MxB impedes the NUP358-mediated HIV-1 pre-integration complex nuclear import and viral replication cooperatively with CPSF6[J]. Linlin Xie. et al. Retrovirology. 2020.
Relationships Among Circulating TNF-α, Skeletal Muscle and Peripheral CD8+ T Cells During Cachexia in Gastric Cancer[J]. Rui Zhao. et al. Cancer Biology. 2020.
HIV-2/SIV Vpx targets a novel functional domain of STING to selectively inhibit cGAS–STING-mediated NF-κB signalling[J]. Jiaming Su. et al. Nature Microbiology. 2019.
LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells[J]. Zunling Li. et al. Cellular & Molecular Immunology. 2019.
KrasG12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer[J]. He Cheng. et al. Cancer Letters. 2019.
MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer[J]. Kun Fan. et al. Cancer Letters. 2018.
